HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely...
